Oncología Hepática
Hospital Universitari Germans Trias i Pujol
Barcelona, EspañaPublikationen in Zusammenarbeit mit Forschern von Hospital Universitari Germans Trias i Pujol (10)
2024
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
Revista espanola de enfermedades digestivas, Vol. 116, Núm. 2, pp. 83-113
-
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH–AEG–SEPD–SEOM–GETECCU
Gastroenterologia y Hepatologia, Vol. 47, Núm. 4, pp. 401-432
-
PET/CT FAPI: Procedure and evidence review in oncology
Revista Espanola de Medicina Nuclear e Imagen Molecular, Vol. 43, Núm. 2, pp. 130-140
2020
-
International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis
Liver International, Vol. 40, Núm. 6, pp. 1467-1476
2019
-
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs
Journal of Hepatology, Vol. 71, Núm. 4, pp. 666-672
-
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules
Journal of Hepatology, Vol. 70, Núm. 5, pp. 874-884
2018
-
Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events
Hepatology, Vol. 67, Núm. 2, pp. 612-622
2017
-
Clinical characteristics of hepatocellular carcinoma in Spain. Comparison with the 2008-2009 period and analysis of the causes of diagnosis out of screening programs. Analysis of 686 cases in 73 centers
Medicina Clinica, Vol. 149, Núm. 2, pp. 61-71
-
Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection
Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237